Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors

C. Sessa, S. Cresta, T. Cerny, J. Baselga, E. Rota Caremoli, A. Malossi, D. Hess, J. Trigo, M. Zucchetti, M. D'Incalci, A. Zaniboni, G. Capri, B. Gatti, P. Carminati, C. Zanna, S. Marsoni, Luca Gianni

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Gimatecan is an orally bioavailable camptothecin analogue with preclinical findings of promising antitumor activity. A phase I design of concerted dose escalation and dosing duration was implemented to assess the potential schedule dependency of tolerability that emerged from animal studies. Patients and methods: Gimatecan was given daily for five consecutive days per week for 1, 2 or 3 weeks every 28 days. Plasma levels of total gimatecan were measured on the first and the last day of treatment in each schedule. Results: Overall, 108 patients were treated with 0.8-7.2mg/m2 of gimatecan per cycle. The main toxicity was myelosuppression with dose-limiting thrombocytopenia. In the 1-, 2- and 3-week schedule, the maximum tolerated doses were 4.5, 5.6 and 6.4 mg/m2. Diarrhea and asthenia were of low grade and of minor clinical relevance, while the higher incidence of nausea and vomiting in the 1-week schedule required the use of antiemetic prophylaxis. Due to the prolonged half-life (∼77 h), the plasma concentration of gimatecan increased from the first to the last day of dosing. Six partial responses were observed. Conclusions: Tolerability of gimatecan was schedule dependent. Further testing with schedules taking into account its long persistence in human plasma is worthwhile.

Original languageEnglish
Pages (from-to)561-568
Number of pages8
JournalAnnals of Oncology
Volume18
Issue number3
DOIs
Publication statusPublished - Mar 2007

Keywords

  • Concerted dose escalation
  • Gimatecan
  • Oral camptothecin
  • Pharmacokinetics
  • Phase I

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors'. Together they form a unique fingerprint.

Cite this